WO2007046186A1 - 腹膜機能検査方法、腹膜機能検査装置並びに腹膜機能検査プログラム - Google Patents
腹膜機能検査方法、腹膜機能検査装置並びに腹膜機能検査プログラム Download PDFInfo
- Publication number
- WO2007046186A1 WO2007046186A1 PCT/JP2006/316434 JP2006316434W WO2007046186A1 WO 2007046186 A1 WO2007046186 A1 WO 2007046186A1 JP 2006316434 W JP2006316434 W JP 2006316434W WO 2007046186 A1 WO2007046186 A1 WO 2007046186A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mtacu
- peritoneal
- function test
- peritoneal function
- drainage
- Prior art date
Links
- 238000012360 testing method Methods 0.000 title claims abstract description 77
- 239000012528 membrane Substances 0.000 title claims abstract description 22
- 238000010998 test method Methods 0.000 title claims description 9
- 238000000502 dialysis Methods 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 19
- 238000004364 calculation method Methods 0.000 claims description 39
- 238000011156 evaluation Methods 0.000 claims description 20
- 238000012546 transfer Methods 0.000 claims description 19
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims description 16
- 230000003204 osmotic effect Effects 0.000 claims description 16
- 239000004202 carbamide Substances 0.000 claims description 13
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 12
- 238000001631 haemodialysis Methods 0.000 claims description 11
- 230000000322 hemodialysis Effects 0.000 claims description 11
- 238000006467 substitution reaction Methods 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 230000035699 permeability Effects 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 3
- 230000007704 transition Effects 0.000 claims description 2
- 230000006870 function Effects 0.000 description 79
- 238000010586 diagram Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 9
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 210000004303 peritoneum Anatomy 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 229960003624 creatine Drugs 0.000 description 4
- 239000006046 creatine Substances 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000013500 data storage Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000000385 dialysis solution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 239000002441 uremic toxin Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010034665 Peritoneal fibrosis Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
- A61M1/1613—Profiling or modelling of patient or predicted treatment evolution or outcome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
Definitions
- Peritoneal function test method Peritoneal function test method, peritoneal function test device, and peritoneal function test program
- the present invention relates to a peritoneal function test method, a peritoneal function test apparatus using a computer, and a peritoneal function test program.
- dialysis refers to various solutes accumulated in the body by metabolic activity (urea (U) as a uremic toxin) by sieving with a molecular weight size through a membrane and removing predetermined molecules by a concentration gradient. , Creatun (Cr), etc.), electrolyte (Ca 2+ , C, Na +, K +), excess water, etc. are eluted from the body fluid into the dialysate, and the dialysate is discarded as waste This helps the patient's reduced renal function.
- metabolic activity urea (U) as a uremic toxin
- peritoneum Blood dialysis (HD; Hemo Dialysis), peritoneum is different depending on the method of purifying blood mechanically by circulating blood extracorporeally or by putting dialysate into the abdominal cavity and purifying blood through the peritoneum.
- PD dialysis
- this method of dialysis has been applied to patients.
- in the case where insufficient renal function cannot be sufficiently supported it is desired to perform an in vitro dialysis treatment using hemodialysis.
- peritoneal dialysis patients mainly perform dialysis at home. The patient himself puts dialysate into the abdominal cavity using a catheter, stores it for several hours, and then repeats the draining step several times a day. The patient should record the amount of excess water excreted from the body at each drainage (water removal amount, etc.), and present it to the doctor at a subsequent examination for a prescription.
- CAPD Continuous Ambulatory Peritoneal Dialysis
- PET peritoneal equilibration tests
- PET was created using the mean and standard deviation of D / PCrea and D / DOglu calculated based on the PET of 100 westerners.
- PET is a simple test method, and the ability to select peritoneal dialysis options according to the category has led to more than 60% of patients having clinical experience in Japan, where clinical usefulness is high.
- a peritoneal dialysis system in which a peritoneal function state of a patient is examined with a computer such as a PC (see JP 2000-140100 A).
- a mathematical model such as Pyle-Popovich, which is known as a macroscopic model of peritoneal dialysis, is calculated from data such as each solute concentration and water removal amount obtained from the PET test. From this, it is possible to examine peritoneal functions such as water removal, MTAC (Overall Mass Transfer 'membrane area coefficient), Kt / V (urea clearance), CCr (creatinine clearance).
- Patent Document 1 JP 2000-140100 A
- Patent Document 2 JP-A-2005-27886
- peritoneal function needs to be considered as a comprehensive evaluation of each function such as solute removal capacity and water removal capacity according to individual patients. From the results of PET tests, parameters such as various solute concentrations and water removal volume Is only calculated. In other words, each parameter is calculated as an independent numerical value in the PET test, and there is no component force to a specific correlation between them. This is a very bottleneck in judging the turning point from peritoneal dialysis to hemodialysis, for example, by the mechanism of peritoneal hyperfunction.
- the MTAC obtained in the PET test is used.
- the peritoneal function is divided into four categories according to the numerical range (High group, High Average group, Low Average group, Low group), and the peritoneal function is grasped according to which category the current patient belongs to, The current and future dialysis plans will be considered.
- each category was considered to have an independent numerical range, but according to the study by the present inventors, a plurality of categories belong to overlapping numerical ranges as shown in FIG. It became clear. As a result, one MTAC value belongs to multiple categories, indicating that the classification accuracy is low.
- the present invention has been made in view of the above-described problems, and a method capable of performing a peritoneal function test on a dialysis patient with higher accuracy than conventional methods while being a relatively simple method. It is an object of the present invention to provide a peritoneal function test apparatus using a sac and a peritoneal function test program.
- the present invention is based on the assumption that MTACu is the total mass transfer of urea nitrogen and the membrane area coefficient is M TACu, and the total mass transfer and membrane area coefficient of Creathun is MTACc.
- MTACu the total mass transfer of urea nitrogen
- M TACu the membrane area coefficient
- Creathun the total mass transfer and membrane area coefficient of Creathun
- the present invention relates to the overall mass transfer / membrane area coefficient of urea nitrogen as MTACu, the overall mass transfer as Creathun's membrane area coefficient as MTACc, the clearance of Creatun as CCr, and the clearance of urea as Kt / V.
- a substitution step of substituting a reference value into at least one of the parameters, and the relation after the substitution step Based on the peritoneal function test result by comparing the calculation step obtained by the equation, the calculation result obtained by the calculation step, the MTACu / c value of the peritoneal function test result, and the drainage amount value Peritoneal permeation
- the peritoneal function test method passed through an evaluation step for evaluating the relationship between the performance and the drainage amount.
- relational expression refers to a relational expression based on the kinetics of peritoneal dialysis.
- the reference value is substituted for CCr and Kt / V, and the relational expression includes a relational expression including MTA Cu / c, which is a ratio of MTACu and MTACc among the four parameters, as a term. Can also be used.
- the relational expression (7) or a modification of the expression (7) can be used as the relational expression.
- the later-described equation (8) or a modified equation of the equation (8) can be used as the relational expression.
- the calculation result and the predetermined peritoneal function test result are plotted against the reference value with respect to a coordinate system having MTACu / c and drainage amount as coordinate axes, respectively.
- the peritoneal function enhancement based on the predetermined peritoneal function test result can also be predicted from the plot position in the coordinate system and the calculation result information.
- the evaluation step when the predetermined peritoneal function test result corresponds to a numerical range in which MTACu / c is 1.44 or less, a numerical range in which the drainage amount can be taken in the numerical range is considered. It is also possible to evaluate the turning points related to the transition from peritoneal dialysis to hemodialysis or the combination of peritoneal dialysis and hemodialysis.
- the total mass transfer membrane area coefficient of urea nitrogen is MTACu
- the total mass transfer of Creatun is MTACc
- the clearance of Creathun is CCr
- the clearance of urea is Kt / V.
- a reference value is substituted into at least one of the parameters, and the relational expression is calculated after the substitution.
- a peritoneal function test apparatus characterized in that a calculation result obtained by calculation is compared with a predetermined peritoneal function test result to evaluate a relationship between peritoneal permeability and a drainage amount based on the peritoneal function test result
- the present invention relates to the total mass transfer of urea nitrogen and membrane area coefficient to MTACu and Creathun, the total mass transfer and membrane area coefficient to MTACc, the clearance of Creathun to CCr, and the clearance of urea to Kt / V, the MTACu, MTACc, CCr, Kt / V Substituting a reference value into at least one of the parameters for the relational expression using the above four parameters, a computing step for performing computation on the relational expression after the substitution step, and the computation Evaluation step to evaluate the relationship between peritoneal permeability and drainage volume based on the peritoneal function test result by comparing the calculated results obtained in the step with the MTACu / c value and drainage volume value of the peritoneal function test result Of the invention as a peritoneal function test program
- the relational expression of the four meters used in the kinetics of the conventional peritoneal dialysis method is used, and this is used as a reference for the drainage amount and MTACu / c as a reference.
- the correlation curve can be obtained and the test results can be compared with each other to evaluate the peritoneal function continuously as MTACu / c and the amount of drainage change numerically over time. It has something.
- FIG. 1 is a schematic diagram of a peritoneal function testing apparatus using a PC as an application example of the present invention.
- FIG. 2 is a functional block diagram showing a configuration of a peritoneal function testing device.
- FIG. 3 is a diagram showing a flow of a peritoneal function test program.
- FIG. 4 is a flowchart of a peritoneal function test program.
- FIG. 5 is a diagram showing an example of a peritoneal function test protocol.
- FIG. 6 This is the input screen for reference values for dialysis guidelines.
- FIG. 8 is a diagram showing a graph display of an MTACu / c-drainage curve and patient data.
- FIG. 9 is a diagram showing the correlation between urea nitrogen in the medium osmotic pressure solution and MTAC of Creatun.
- FIG. 10 is a diagram showing the relationship between the PET category and MTACu / c.
- FIG. 11 is a graph showing the relationship between MTACu / c of medium osmotic pressure solution and drainage of 4-hour storage.
- FIG. 12 is a diagram showing the correlation between Kt / V and CCr.
- FIG. 13 is a diagram showing the correlation between Kt / V and CCr.
- FIG. 14 is a diagram showing coordinates representing an MTACu / c-drainage curve.
- FIG. 15 is a diagram schematically showing a mass transfer mechanism in peritoneal dialysis.
- the peritoneal function test apparatus is also used as a dialysis planning apparatus, and is configured by introducing a program (peritoneal function test program) for executing a peritoneal dialysis test method into a general-purpose computer.
- FIG. 1 shows a configuration example of the peritoneal function testing device of the present invention.
- the apparatus includes a main body 11 having a known CPU, a hard disk drive (HDD), a memory, and the like inside, a keyboard 12 and a mouse 13 as input means connected to the main body, data output means (display part)
- a personal computer (PC) 1 having a monitor 10 is shown.
- the peritoneal function test program of the present invention may be read into the PCI side from various portable recording media 20 (CD-ROM 201, DVD-ROM 202, flexible disk 203, memory card 204, etc.), for example, as shown in FIG.
- the data may be read from the storage device 30 such as another server or PC via the communication line to the PC1 side.
- the peritoneal function test program is stored on the HDD in PC1 along with the patient data!
- the configuration of the apparatus is divided into an input unit 40, a storage unit 50, a calculation unit 60, and an output unit 70 as shown in FIG.
- the input means 40 has a reference value input unit 401 and a patient data input unit 402 related to the PET test result.
- the reference value input unit 401 is a means for inputting reference values for the four kinetic parameters used in the calculation of equation (7) described later.
- the storage unit 50 (HDD) is operated by the storage unit 502 for storing patient data input by the input unit 40 and the calculation unit 60 based on the numerical value input by the reference value input unit 40.
- MTACu / c-drainage curve storage unit 501 for storing the results.
- the calculation unit 60 (CPU) mainly performs calculations based on the program and manages each data stored in the storage unit 50.
- the output means 70 (monitor 10) includes an MTACu / c that is a result of calculation by the calculation unit 60 and a MTACu / c that displays a drainage amount curve, a drainage amount curve output unit 701, and the patient data storage.
- the reference values are substituted into CCr and Kt / V taken by the predetermined dialysis guideline selected by the operator, Calculation is performed on a relational expression (equation (7) described later) including four kinetic parameters (CCr, Kt / V, MTACu, MTACc).
- a curve showing the relationship between the MTACu / c obtained from the calculation result and the amount of drainage is displayed on the monitor, and the PET data of the patient prepared separately is also displayed.
- Peritoneal function can be evaluated based on the relative position of the patient data and the reference curve.
- FIG. 3 is a diagram showing the overall flow of the peritoneal function test program introduced into PC1.
- Fig. 4 is a flowchart of this program.
- t is the storage time
- V is the drainage liquid that has stored the medium osmotic pressure solution for a predetermined time (here 4 hours)
- PC1 shows a curve (MTACu / c-drainage curve) showing the relationship between the MTAC ratio (MTACu / c) of urea nitrogen and creatine obtained from the result of the calculation step and the drainage amount.
- a graph is displayed on the monitor 10 (graphic step, S103 in FIG. 4).
- the calculation result relating to the curve is stored in the storage unit 501 as the MTACu / c-drainage amount curve in the storage means 50 of the PC 1.
- the program steps need only execute S104 to S106 at the time of starting the apparatus for the second and subsequent times after the result calculated by S103 is stored in the storage unit 501. That is, the screen display of FIG. 6 is performed after the program is started, and a graph display (S 104) is performed for the curve stored in the storage unit 501 by simply pressing a radio button for selecting a predetermined curve. Can do.
- FIG. 5 is a data acquisition step diagram for the PET test at this time.
- the volume of 2 L of 400 (mOsm / kg-solvent) medium dialysis solution is used alternately, and the patient is exchanged a total of 4 times at a daily force of about 3-8 hours.
- blood is collected regularly, and each solute concentration is collected and urine is stored.
- the osmotic pressure of the dialysate and the number of exchanges may be other than this.
- the items of clinical data obtained in this way are a data group of urine accumulation amount and each solute concentration in urine (urine-urea nitrogen * urine 'creaturen, urine' protein protein, urine / sodium). Data are also obtained on the concentration of total protein, albumin, serum creatine, urea nitrogen, glucose, sodium, chlor, etc., obtained by collecting blood. Needless to say, the PET test may use data measured in advance.
- the operator uses the input screen displayed on the monitor to input the results of the PET test (MTACu and MTACc) to the PC (PET data input step, Fig. 4, S 105).
- PC1 plots and displays the patient data in the graph along with the MTACu / c-drainage curve (S105 in Fig. 8 and Fig. 4). ) This enables the operator to examine the peritoneal function based on the relative position between the plotted PET test result data position and the curve (evaluation step in FIG. 3). It is a main feature of the present invention that the peritoneal function test can be performed by using such a graph.
- Patient X data obtained from the PET study showed an MTACu / c value of 1.66 and a total drainage volume of 10L.
- the operator selects one of the NKF-DOQI guideline, CANUSA Study guideline, and DOQI guideline that are preset as screen force reference values shown in Fig. 6 (here, the NKF-DOQI guideline is selected).
- the types of reference values are not limited to those in the above guidelines, but the NKF-DOQI guide If it is a drain, it can be used as a sufficiently reliable reference value. In addition, if the strictest guidelines among the existing main guidelines are adopted, there is an effect of preventing excessive peritoneal stress due to peritoneal dialysis.
- the graph display of FIG. 8 is obtained in which the data of patient X is plotted against the MTACu / c-drainage curve.
- the ideal drainage volume when MTACu / c is 1.66 in the NKF-DOQI guideline is approximately 13L.
- the amount of drainage is not obtained, and it can be seen that the amount of drainage is insufficient for this guideline. Therefore, the dialysis intensity in the current peritoneal dialysis plan is insufficient, and it can be said that it is necessary to increase the number of peritoneal dialysis in the future or to consider combination therapy with hemodialysis.
- the turning point between peritoneal dialysis and hemodialysis is accurately determined by grasping the relative position between the curve and patient data and the change in the slope of the curve. Since it can be predicted, for example, if a peritonitis that may occur due to excessive peritoneal dialysis is prevented in advance, a high effect can be expected. This Thus, it is possible to extend the life of the patient under appropriate dialysis planning.
- the peritoneal function testing device has the main characteristics in the calculation based on Equation (7) and the contents of the graph display.
- a separate special device, calculation method, or so far has been used to realize the function. There is no need for any new data that has not been used. For this reason, it has features that can be easily realized based on the conventional PET test data at a low cost.
- Equation (7) used in the present invention also derives the existing MTAC derivation force, it can be used relatively simply and easily.
- FIG. 15 is a model used to explain a general peritoneal dialysis function.
- molecular diffusion and convection occur in solutes such as urea nitrogen and creatine between body fluids such as blood and lymph fluid and dialysate through the peritoneum.
- the parameter representing the peritoneal function at this time is expressed as KA (MTAC; overall mass transfer / membrane area coefficient) or Kt / V.
- V (0) is the injection volume
- V is the drainage volume after storing the medium osmotic pressure solution for 4 hours
- C (0) is the solute concentration in the intraperitoneal dialysate immediately after the injection of the medium osmotic pressure solution
- C is the medium osmotic pressure solution
- n 0
- n 0.5
- Yamashita's equation 0.5
- n 1.0
- Babb-Garred's equation n can take any of these three kinds of numerical values.
- n 0 (when Henderson's equation is applied) (the ratio of MTAC of urea nitrogen and Creatun calculated by 1 (MTACu / c) and medium osmotic pressure stored for 4 hours)
- the force required to determine the correlation between the dialysate drainage volume The drainage volume is the average of the PET NAVI test PET drainage volume and the medium osmotic dialysate drainage volume stored for 4 to 5 hours.
- the calculation is performed by calculating the creatinine clearance (CCr) and urea nitrogen taralance (Kt).
- MTACu is calculated based on the amount of drainage and dialysis volume. Organizing equation (5)
- a PET test was conducted on 100 patients with peritoneal dialysis who performed stable CAPD, CCPD (continuous periodic peritoneal dialysis) and NIPD (night peritoneal dialysis).
- Table 1 shows the average clinical data.
- the total body fluid volume and body surface area are the average values of Ota et al. (Kazuo Ota, Kaoru Ishizaki, Atsushi Sanaka, Hidemune Naito, et al. “Clinical laboratory data survey report of CAPD patients. Peritoneal dialysis '99” supervised by Kazuo Ota, pp383-391 Tokyo Medical Co., Tokyo, 1999).
- Fig. 9 shows the correlation between urea nitrogen MTAC and Creatun MTAC in all cases.
- MTAC between small molecules showed a good correlation (r 2 > 0.58).
- the solute diffusion coefficient is proportional to the -0.5 power of the molecular weight. It can be confirmed that the correlation between urea and Creatun is approximately linearly approximated. This means that the M TACu / c value in each patient can be viewed as constant, even though there are differences in the individual MTAC values themselves.
- Fig. 2 shows the relationship between MTACu / c and PET category for all cases, and Table 2 shows the average value of MT ACu / c for each PET category.
- MTACu / c decreases with increased peritoneal function.
- the possible range of MTACu / c in each category is the Dialysate / Plasma ratio (D / P ) And the storage time in the coordinate system (so-called D / P curve).
- D / P Dialysate / Plasma ratio
- Fig. 11 shows the correlation between the MTACu / c of the medium osmotic dialysate and the amount of water removed after 4-hour storage.
- MTACu / c correlates with dulcose MTAC, and that MTACu / c correlates with ultrafiltration capacity.
- MTAC is an index that regulates peritoneal permeability, it has been suggested that it can also be applied to the evaluation of ultrafiltration capacity in Fig. 1. Previously, there was no index that could evaluate peritoneal permeability and ultrafiltration capacity at the same time, but this suggests that MTACu / c is useful for peritoneal function analysis in the present invention.
- Fig. 14 suggests that the low transporter can be formulated without using medium osmotic dialysate, considering that the remaining renal function is preserved with a shallow history of peritoneal dialysis.
- High transporters with MTACu / c ⁇ 1.76 are evaluated as having a higher daily drainage volume than low transporters in order to secure these dialysis volumes.
- MTACu / c ⁇ 1.44 MTACu / c ⁇ mean standard deviation
- the PET test was performed using a medium osmotic pressure solution as a dialysis solution and storing for 4 hours.
- the storage time may be set as appropriate.
- the dialysis guideline separately prepared by an operator or the like can be used.
- the reference values used for the above four kinetic parameters can be obtained directly from the PET test described above, as well as the PC peritoneal dialysis management software for PC test data (for example, the application “PDC” manufactured by Gumbro Inc., manufactured by Boxter) You can use the application “PD ADEQUEST”) to perform a simulation and acquire it.
- the reference value can be obtained by managing and calculating PET test data using a combination therapy planning device. is there.
- the present invention can be used for examination of dialysis planning in peritoneal dialysis and hemodialysis.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- External Artificial Organs (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/083,094 US8303532B2 (en) | 2005-10-18 | 2006-08-22 | Pertioneal membrane function test method, peritoneal membrane function test apparatus and peritoneal membrane function test program |
CN200680039035XA CN101291696B (zh) | 2005-10-18 | 2006-08-22 | 腹膜功能检查装置 |
CA002624161A CA2624161A1 (en) | 2005-10-18 | 2006-08-22 | Peritoneal membrane function test method, peritoneal membrane function test apparatus and peritoneal membrane function test program |
EP06796648A EP1938848A4 (en) | 2005-10-18 | 2006-08-22 | METHOD, APPARATUS AND PROGRAM FOR TESTING PERITONEAL MEMBRANE FUNCTION |
JP2007540894A JP4968074B2 (ja) | 2005-10-18 | 2006-08-22 | 腹膜機能検査装置並びに腹膜機能検査プログラム |
HK09103508.0A HK1123759A1 (en) | 2005-10-18 | 2009-04-16 | Peritoneal membrane function test apparatus |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-302958 | 2005-10-18 | ||
JP2005302958 | 2005-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007046186A1 true WO2007046186A1 (ja) | 2007-04-26 |
Family
ID=37962285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/316434 WO2007046186A1 (ja) | 2005-10-18 | 2006-08-22 | 腹膜機能検査方法、腹膜機能検査装置並びに腹膜機能検査プログラム |
Country Status (8)
Country | Link |
---|---|
US (1) | US8303532B2 (ja) |
EP (1) | EP1938848A4 (ja) |
JP (1) | JP4968074B2 (ja) |
KR (1) | KR20080066679A (ja) |
CN (1) | CN101291696B (ja) |
CA (1) | CA2624161A1 (ja) |
HK (1) | HK1123759A1 (ja) |
WO (1) | WO2007046186A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009183558A (ja) * | 2008-02-07 | 2009-08-20 | Jms Co Ltd | 血液透析装置 |
JP2012532669A (ja) * | 2009-07-07 | 2012-12-20 | バクスター・インターナショナル・インコーポレイテッド | 腹膜透析のための簡易化された腹膜平衡試験 |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8882700B2 (en) | 2008-05-02 | 2014-11-11 | Baxter International Inc. | Smart patient transfer set for peritoneal dialysis |
US9348975B2 (en) | 2008-05-02 | 2016-05-24 | Baxter International Inc. | Optimizing therapy outcomes for peritoneal dialysis |
US8168063B2 (en) * | 2008-07-09 | 2012-05-01 | Baxter International Inc. | Dialysis system having filtering method for determining therapy prescriptions |
US7981281B2 (en) * | 2008-07-09 | 2011-07-19 | Baxter International, Inc. | Dialysis system having regimen generation methodology |
US8057679B2 (en) | 2008-07-09 | 2011-11-15 | Baxter International Inc. | Dialysis system having trending and alert generation |
EP2391404B1 (en) * | 2009-01-30 | 2013-01-16 | Baxter International Inc. | Transfer sets for therapy optimization |
US8521482B2 (en) * | 2009-02-20 | 2013-08-27 | Baxter International Inc. | Simulation of patient drain phase in peritoneal dialysis |
US8282829B2 (en) | 2009-05-20 | 2012-10-09 | Baxter International Inc. | System and method for automated data collection of twenty-four hour ultrafiltration and other patient parameters using wired or wireless technology |
US9020827B2 (en) | 2009-10-16 | 2015-04-28 | Baxter International Inc. | Peritoneal dialysis optimized using a patient hand-held scanning device |
EP2747808B1 (en) | 2011-08-22 | 2016-11-30 | Medtronic Inc. | Dual flow sorbent cartridge |
EP2800592B1 (en) | 2012-01-04 | 2019-03-06 | Medtronic Inc. | Multi-staged filtration system for blood fluid removal |
US11154648B2 (en) | 2013-01-09 | 2021-10-26 | Medtronic, Inc. | Fluid circuits for sorbent cartridge with sensors |
US9707328B2 (en) | 2013-01-09 | 2017-07-18 | Medtronic, Inc. | Sorbent cartridge to measure solute concentrations |
US11565029B2 (en) | 2013-01-09 | 2023-01-31 | Medtronic, Inc. | Sorbent cartridge with electrodes |
US9713666B2 (en) | 2013-01-09 | 2017-07-25 | Medtronic, Inc. | Recirculating dialysate fluid circuit for blood measurement |
US10010663B2 (en) | 2013-02-01 | 2018-07-03 | Medtronic, Inc. | Fluid circuit for delivery of renal replacement therapies |
US10850016B2 (en) | 2013-02-01 | 2020-12-01 | Medtronic, Inc. | Modular fluid therapy system having jumpered flow paths and systems and methods for cleaning and disinfection |
US9623164B2 (en) | 2013-02-01 | 2017-04-18 | Medtronic, Inc. | Systems and methods for multifunctional volumetric fluid control |
US9144640B2 (en) | 2013-02-02 | 2015-09-29 | Medtronic, Inc. | Sorbent cartridge configurations for improved dialysate regeneration |
US9827361B2 (en) | 2013-02-02 | 2017-11-28 | Medtronic, Inc. | pH buffer measurement system for hemodialysis systems |
US9884145B2 (en) | 2013-11-26 | 2018-02-06 | Medtronic, Inc. | Parallel modules for in-line recharging of sorbents using alternate duty cycles |
US9943780B2 (en) | 2013-11-26 | 2018-04-17 | Medtronic, Inc. | Module for in-line recharging of sorbent materials with optional bypass |
US10004839B2 (en) | 2013-11-26 | 2018-06-26 | Medtronic, Inc. | Multi-use sorbent cartridge |
US9895477B2 (en) | 2013-11-26 | 2018-02-20 | Medtronic, Inc. | Detachable module for recharging sorbent materials with optional bypass |
US10052612B2 (en) | 2013-11-26 | 2018-08-21 | Medtronic, Inc. | Zirconium phosphate recharging method and apparatus |
US10537875B2 (en) | 2013-11-26 | 2020-01-21 | Medtronic, Inc. | Precision recharging of sorbent materials using patient and session data |
WO2015199768A1 (en) | 2014-06-24 | 2015-12-30 | Medtronic, Inc. | Stacked sorbent assembly |
EP3160532B1 (en) | 2014-06-24 | 2019-09-18 | Medtronic Inc. | A urease introduction system for replenishing urease in a sorbent cartridge |
EP3160529B1 (en) | 2014-06-24 | 2019-11-13 | Medtronic Inc. | Replenishing urease in dialysis systems using urease pouches |
WO2015199766A1 (en) | 2014-06-24 | 2015-12-30 | Medtronic, Inc. | Modular dialysate regeneration assembly |
WO2015199760A1 (en) | 2014-06-24 | 2015-12-30 | Medtronic, Inc. | Replenisihing urease in dialysis systems using a urease introducer |
WO2015199761A1 (en) | 2014-06-24 | 2015-12-30 | Medtronic, Inc. | Sorbent pouch |
US10874787B2 (en) | 2014-12-10 | 2020-12-29 | Medtronic, Inc. | Degassing system for dialysis |
US9713665B2 (en) | 2014-12-10 | 2017-07-25 | Medtronic, Inc. | Degassing system for dialysis |
US10098993B2 (en) | 2014-12-10 | 2018-10-16 | Medtronic, Inc. | Sensing and storage system for fluid balance |
US10981148B2 (en) | 2016-11-29 | 2021-04-20 | Medtronic, Inc. | Zirconium oxide module conditioning |
US11167070B2 (en) | 2017-01-30 | 2021-11-09 | Medtronic, Inc. | Ganged modular recharging system |
US10960381B2 (en) | 2017-06-15 | 2021-03-30 | Medtronic, Inc. | Zirconium phosphate disinfection recharging and conditioning |
US11278654B2 (en) | 2017-12-07 | 2022-03-22 | Medtronic, Inc. | Pneumatic manifold for a dialysis system |
US11033667B2 (en) | 2018-02-02 | 2021-06-15 | Medtronic, Inc. | Sorbent manifold for a dialysis system |
US11110215B2 (en) | 2018-02-23 | 2021-09-07 | Medtronic, Inc. | Degasser and vent manifolds for dialysis |
US11213616B2 (en) | 2018-08-24 | 2022-01-04 | Medtronic, Inc. | Recharge solution for zirconium phosphate |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000140100A (ja) * | 1998-08-21 | 2000-05-23 | Jms Co Ltd | 腹膜透析システム |
JP2000271127A (ja) * | 1999-03-26 | 2000-10-03 | Terumo Corp | 腹膜機能評価システム及びその制御方法、コンピュータ可読メモリ |
JP2003275302A (ja) * | 2002-03-26 | 2003-09-30 | Jms Co Ltd | 腹膜透析システム及び方法 |
JP2004358230A (ja) * | 2003-05-14 | 2004-12-24 | Jms Co Ltd | 腹膜機能検査方法および腹膜透析プランニング装置 |
JP2005027886A (ja) * | 2003-05-14 | 2005-02-03 | Jms Co Ltd | 腹膜透析および血液透析併用プランニング方法ならびに腹膜透析および血液透析併用プランニング装置 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5670057A (en) * | 1995-04-28 | 1997-09-23 | Baxter International Inc. | Apparatus and method for automatically performing peritoneal equilibration tests |
-
2006
- 2006-08-22 WO PCT/JP2006/316434 patent/WO2007046186A1/ja active Application Filing
- 2006-08-22 CA CA002624161A patent/CA2624161A1/en not_active Abandoned
- 2006-08-22 KR KR1020087009250A patent/KR20080066679A/ko not_active Application Discontinuation
- 2006-08-22 EP EP06796648A patent/EP1938848A4/en not_active Withdrawn
- 2006-08-22 JP JP2007540894A patent/JP4968074B2/ja active Active
- 2006-08-22 CN CN200680039035XA patent/CN101291696B/zh active Active
- 2006-08-22 US US12/083,094 patent/US8303532B2/en not_active Expired - Fee Related
-
2009
- 2009-04-16 HK HK09103508.0A patent/HK1123759A1/xx unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000140100A (ja) * | 1998-08-21 | 2000-05-23 | Jms Co Ltd | 腹膜透析システム |
JP2000271127A (ja) * | 1999-03-26 | 2000-10-03 | Terumo Corp | 腹膜機能評価システム及びその制御方法、コンピュータ可読メモリ |
JP2003275302A (ja) * | 2002-03-26 | 2003-09-30 | Jms Co Ltd | 腹膜透析システム及び方法 |
JP2004358230A (ja) * | 2003-05-14 | 2004-12-24 | Jms Co Ltd | 腹膜機能検査方法および腹膜透析プランニング装置 |
JP2005027886A (ja) * | 2003-05-14 | 2005-02-03 | Jms Co Ltd | 腹膜透析および血液透析併用プランニング方法ならびに腹膜透析および血液透析併用プランニング装置 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009183558A (ja) * | 2008-02-07 | 2009-08-20 | Jms Co Ltd | 血液透析装置 |
JP2012532669A (ja) * | 2009-07-07 | 2012-12-20 | バクスター・インターナショナル・インコーポレイテッド | 腹膜透析のための簡易化された腹膜平衡試験 |
Also Published As
Publication number | Publication date |
---|---|
EP1938848A4 (en) | 2012-09-19 |
CA2624161A1 (en) | 2007-04-26 |
US20090271119A1 (en) | 2009-10-29 |
HK1123759A1 (en) | 2009-06-26 |
JP4968074B2 (ja) | 2012-07-04 |
KR20080066679A (ko) | 2008-07-16 |
JPWO2007046186A1 (ja) | 2009-04-23 |
US8303532B2 (en) | 2012-11-06 |
CN101291696A (zh) | 2008-10-22 |
EP1938848A1 (en) | 2008-07-02 |
CN101291696B (zh) | 2012-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007046186A1 (ja) | 腹膜機能検査方法、腹膜機能検査装置並びに腹膜機能検査プログラム | |
US8449496B2 (en) | Method for testing peritoneum function and a peritoneal dialysis planning apparatus | |
Hakim et al. | Adequacy of hemodialysis | |
US8088094B2 (en) | Planning method and apparatus for peritoneal dialysis and hemodialysis hybrid remedy | |
US8180574B2 (en) | Simplified peritoneal equilibration test for peritoneal dialysis | |
JPWO2004006776A1 (ja) | 腹膜機能に関する検査方法 | |
EP3697466B1 (en) | Methods for detecting access recirculation | |
JP3402360B2 (ja) | 腹膜透析システム | |
JP4968349B2 (ja) | 腹膜機能検査方法および腹膜透析プランニング装置 | |
Flessner | Computerized kinetic modeling: a new tool in the quest for adequacy in peritoneal dialysis | |
CN116189837A (zh) | 一种无创的血清尿素氮浓度评估方法及其系统 | |
Ray et al. | Support vector machine for determining dose of dialysis | |
Hamada et al. | Development of a computer-aided diagnosis system for continuous peritoneal dialysis: an availability of the simultaneous numerical optimization technique for kinetic parameters in the peritoneal dialysis model | |
Ford | THE HISTORY AND DEVELOPMENT OF UREA KINETIC MODELLING | |
Appendices | Hemodialysis (HD) Adequacy 1. HD Adequacy CPM I: Monthly Measurement of Delivered Hemodialysis Dose. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680039035.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2007540894 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006796648 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2624161 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12083094 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087009250 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |